2-C-Methylerythritol 4-phosphate: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{Biochemistry-stub}} | {{Biochemistry-stub}} | ||
{{Pharmacology-stub}} | {{Pharmacology-stub}} | ||
{{No image}} | |||
Revision as of 04:49, 10 February 2025
2-C-Methylerythritol 4-phosphate (MEP) is a critical intermediate in the non-mevalonate pathway (also known as the MEP/DOXP pathway) of isoprenoid biosynthesis. This pathway is responsible for the production of essential isoprenoids in most bacteria, algae, and plants, but is absent in animals, making it an interesting target for the development of antibiotics, herbicides, and antimalarial drugs.
Biosynthesis
The MEP pathway begins with the condensation of pyruvate and glyceraldehyde 3-phosphate (G3P) to produce 1-deoxy-D-xylulose 5-phosphate (DXP). Through a series of enzymatic reactions, DXP is then converted to 2-C-methylerythritol 4-phosphate. The enzyme IspE catalyzes the conversion of MEP to 4-diphosphocytidyl-2-C-methyl-D-erythritol, a further step in the pathway leading to the production of isoprenoids.
Function
Isoprenoids, the products of the MEP pathway, are a large and diverse group of molecules that play crucial roles in various biological processes. They are involved in the synthesis of chlorophylls, carotenoids, plant hormones, and quinones. In bacteria, isoprenoids are essential for the synthesis of cell membrane constituents and electron transport chain components.
Clinical Significance
Due to its absence in humans, the MEP pathway is an attractive target for the development of new antimicrobial and antiparasitic agents. Inhibitors of the MEP pathway enzymes have shown potential as antibiotics against a range of bacteria and as antimalarial agents. For example, fosmidomycin, an inhibitor of the enzyme DOXP reductoisomerase (which acts early in the MEP pathway), has shown efficacy against Plasmodium falciparum, the parasite responsible for malaria.
Research
Research into the MEP pathway and its inhibitors is ongoing, with the aim of developing new therapeutic agents. Understanding the structure and function of the enzymes involved in the MEP pathway is crucial for the design of effective inhibitors.
See Also
External Links

This article is a biochemistry stub. You can help WikiMD by expanding it!
